Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 6/2015

01-06-2015 | Original Research Article

Clopidogrel Versus Aspirin in Patients with Recent Ischemic Stroke and Established Peripheral Artery Disease: An Economic Evaluation in a Chinese Setting

Authors: Te Li, Maobai Liu, He Ben, Zhenxing Xu, Han Zhong, Bin Wu

Published in: Clinical Drug Investigation | Issue 6/2015

Login to get access

Abstract

Background and Objectives

Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD). We compared the cost effectiveness of clopidogrel with that of aspirin in Chinese patients with recent IS or established PAD.

Methods

A discrete-event simulation was developed to evaluate the economic implications of secondary prevention with clopidogrel versus aspirin. All available evidence was derived from clinical studies. Costs from a Chinese healthcare perspective in 2013 US dollars and quality-adjusted life-years (QALYs) were projected over patients’ lifetimes. Uncertainties were addressed using sensitivity analyses.

Results

Compared with aspirin, clopidogrel yielded a marginally increased life expectancy by 0.46 and 0.21 QALYs at an incremental cost-effectiveness ratio of $US5246 and $US9890 per QALY in patients with recent IS and established PAD, respectively. One-way sensitivity analyses showed that the evaluation of patients with PAD and recent IS was robust except for the parameter of patient age. Given a willingness-to-pay of $US19,877 per QALY gained, clopidogrel had a probability of 90 and 68 % of being cost effective in the recent IS or established PAD subgroups compared with aspirin, respectively.

Conclusions

The analysis suggests that clopidogrel for secondary prevention is cost effective for patients with either PAD or recent IS in a Chinese setting in comparison with aspirin.
Literature
1.
Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med. 1998;3(3):231–9.CrossRefPubMed
2.
Mohler ER 3rd. Atherothrombosis—wave goodbye to combined anticoagulation and antiplatelet therapy? N Engl J Med. 2007;357(3):293–6.CrossRefPubMed
3.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292.CrossRefPubMed
4.
Smith SC Jr, Zheng ZJ. The impending cardiovascular pandemic in China. Circ Cardiovasc Qual Outcomes. 2010;3(3):226–7.CrossRefPubMed
5.
Antithrombotic Trialists Colloboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
6.
Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):e215–367.CrossRefPubMed
7.
Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e637S–68S.PubMedCentralPubMed
8.
Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817–25.CrossRefPubMed
9.
Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.CrossRefPubMed
10.
Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–89.CrossRefPubMed
11.
Sacco RL, Diener H-C, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238–51.CrossRefPubMedCentralPubMed
12.
Yusuf S, Fox KAA, Tognoni G, Mehta SR, Chrolavicius S, Anand S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.CrossRefPubMed
13.
Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–21.CrossRefPubMed
14.
Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–39.CrossRef
15.
Kourlaba G, Fragoulakis V, Maniadakis N. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. Appl Health Econ Health Policy. 2012;10(5):331–42.CrossRefPubMed
16.
Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med. 2004;116(12):797–806.CrossRefPubMed
17.
Karnon J, Brennan A, Pandor A, Fowkes G, Lee A, Gray D, et al. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin. 2005;21(1):101–12.CrossRefPubMed
18.
Berger K, Hessel F, Kreuzer J, Smala A, Diener HC. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin. 2008;24(1):267–74.CrossRefPubMed
19.
Annemans L, Lamotte M, Levy E, Lenne X. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J Med Econ. 2003;6(1–4):55–68.CrossRef
20.
Chinese Society of Cardiology of Chinese Medical. A, Editorial Board of Chinese Journal of Cardiology. Expert consensus of antiplatelet therapy in cardiovascular disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41(3):183–94.
21.
Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Moller J, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Value Health. 2012;15(6):821–7.CrossRefPubMed
22.
Wu S, Shi Y, Wang C, Jia Q, Zhang N, Zhao X, et al. Glycated hemoglobin independently predicts stroke recurrence within one year after acute first-ever non-cardioembolic strokes onset in a Chinese cohort study. PloS One. 2013;8(11):e80690.CrossRefPubMedCentralPubMed
23.
Tang HQ, Yang LL, Hu SL, Shen G, Sun YH, Huang XH, et al. Effects of low-dose aspirin on primary prevention of cardiovascular events: a systematic review. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38(4):315–20.PubMed
24.
Dippel DW. The results of CAPRIE, IST and CAST. Clopidogrel vs. aspirin in patients at risk of ischaemic events. International Stroke Trial. Chinese Acute Stroke Trial. Thromb Res. 1998;92(1 Suppl 1):S13–6.
25.
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641–9.
26.
Jahn B, Theurl E, Siebert U, Pfeiffer KP. Tutorial in medical decision modeling incorporating waiting lines and queues using discrete event simulation. Value Health. 2010;13(4):501–6.CrossRefPubMed
27.
Task Group of the Chinese Guidelines for Pharmacoeconomic Evaluations. China guidelines for pharmacoeconomic evaluations. China J Pharm Econ. 2011(3):7–48.
28.
Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010;13(5):592–600.CrossRefPubMed
29.
Suto Y, Kowa H, Nakayasu H, Awaki E, Saito J, Irizawa Y, et al. Relationship between three-year survival and functional outcome at discharge from acute-care hospitals in each subtype of first-ever ischemic stroke patients. Intern Med. 2011;50(13):1377–83.CrossRefPubMed
30.
Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562–70.CrossRefPubMed
31.
Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105(5):908–19.CrossRefPubMed
32.
Sivenius J, Cunha L, Diener HC, Forbes C, Laakso M, Lowenthal A, et al. Antiplatelet treatment does not reduce the severity of subsequent stroke. European Stroke Prevention Study 2 Working Group. Neurology. 1999;53(4):825–9.CrossRefPubMed
33.
34.
Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis—introduction. Health Technol Assess. 2004;8(11):1–91.
35.
Wu B, Kun L, Liu X, He B. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cardiovasc Drugs Ther. 2014;28(1):87–98.CrossRefPubMed
36.
37.
Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–28.CrossRefPubMed
38.
Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–51.CrossRefPubMed
39.
Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care. 2011;49(3):267–72.CrossRefPubMed
40.
Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012;15(6):843–50.CrossRefPubMed
41.
Juul N, Gislason G, Olesen JB, Lamberts M, Hansen ML, Karasoy D, et al. Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups. Epub: Eur Heart J Acute Cardiovasc Care; 2014.
42.
Diener HC, Ringleb PA, Savi P. Clopidogrel for the secondary prevention of stroke. Expert Opin Pharmacother. 2005;6(5):755–64.CrossRefPubMed
43.
Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23(4):323–32.CrossRefPubMed
44.
McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119(8):624–38.CrossRefPubMed
45.
Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. J Med Assoc Thai. 2009;92(Suppl 6):S19–26.PubMed
46.
Yothasamut J, Tantivess S, Teerawattananon Y. Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable? Value Health. 2009;12(Suppl 3):S26–30.CrossRefPubMed
Metadata
Title
Clopidogrel Versus Aspirin in Patients with Recent Ischemic Stroke and Established Peripheral Artery Disease: An Economic Evaluation in a Chinese Setting
Authors
Te Li
Maobai Liu
He Ben
Zhenxing Xu
Han Zhong
Bin Wu
Publication date
01-06-2015
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 6/2015
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-015-0290-x

Other articles of this Issue 6/2015

Clinical Drug Investigation 6/2015 Go to the issue

Adis Drug Evaluation

Diclofenac Sodium Injection (Akis®, Dicloin®): A Review of Its Use in the Management of Pain

Letter to the Editor

Comment on: Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies

Original Research Article

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects

Original Research Article

Efficacy and Safety of Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream in Chinese Patients with Melasma: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study

Systematic Review

Comparison of Glyburide with Metformin in Treating Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis

Original Research Article

Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men